Judge temporarily blocks Colorado’s first-in-the-nation price cap on a prescription drug

A federal judge has issued a preliminary injunction to block Colorado’s first-in-the-nation price cap on the prescription drug Enbrel, citing conflicts with federal patent law. Chief Judge Daniel D. Domenico ruled that the state’s attempt to regulate the price of patented medications is likely preempted by federal statutes designed to protect pharmaceutical innovation and research investments. This decision represents a significant setback for state-level efforts to control healthcare costs through Prescription Drug Affordability Boards and reinforces federal protections for the pharmaceutical industry.

Chief Judge Daniel D. Domenico of the U.S. District Court in Denver granted a preliminary injunction against the Colorado Prescription Drug Affordability Board’s (PDAB) price cap on Enbrel, an autoimmune treatment manufactured by Amgen. The PDAB had sought to implement an "upper payment limit" of approximately $31,000 per year for the drug, which currently carries a wholesale cost of roughly $96,000 and a net cost of $58,000 after rebates. The cap was scheduled to take effect in 2027, but Amgen successfully argued that the restriction would cause irreparable economic harm and undermine the federal patent system by interfering with the financial incentives granted to patent holders.

The court’s decision relied heavily on federal precedent involving the District of Columbia, which established that state-level price controls on patented drugs are preempted by federal law. Judge Domenico noted that federal patent law intentionally grants pharmaceutical companies temporary monopolies to allow them to recoup research and development costs by setting their own prices. The ruling rejected the state’s argument that the complex pharmaceutical supply chain would prevent Amgen from suffering direct financial losses, with the judge concluding that the cap would inevitably result in lower revenue for the manufacturer during negotiations with wholesalers and other purchasers.

This ruling poses a direct challenge to the authority of Colorado’s PDAB and similar boards established in other states to curb rising medication costs. While the board is currently reviewing other drugs like Stelara and Cosentyx for potential price limits, the injunction suggests that patented medications may remain shielded from state-level price intervention until the underlying lawsuit is resolved. While consumer advocacy groups like the Colorado Consumer Health Initiative criticized the move as a blow to affordability, Amgen expressed satisfaction with the decision, viewing it as a vital protection of the federal incentives that drive medical innovation.